NCT03384316 2020-09-09
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
National Institutes of Health Clinical Center (CC)
Mary Crowley Medical Research Center
H. Lee Moffitt Cancer Center and Research Institute